Venture Capital

Hexagon Bio Closes $47M In Series A Financing To Advance Novel Oncology And Infectious Disease Therapies

by vcaonline.com posted 1week ago 211 views
Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies - The company is building a first-of-its-kind proprietary genomics database to reveal new secondary metabolites to combat human disease MENLO PARK, Calif., September 15, 2020-- Hexagon Bio, Inc. ("Hexagon"), a biotechnology company turning nature's genomes into medicines, today announced that it has closed $47 million in Series A financing. The round was led by The Column Group, with participation from 8VC and Two Sigma Ventures.

In this article